New tool using 2D images to measure cancer risk
the ONA take:
Portuguese researchers developed a method of identifying cancer risk that uses images of a protein in a population of cells to quantify how much of the protein and where it is in the cell. The novel method was tested on cells with mutated e-cadherin, a tumor suppressor protein.
The mutation produces malfunctioning e-cadherin that causes human diffuse gastric cancer (HDGC). Gastric cancer is the fourth most common type of cancer in the world, and up to 3% of cases are HDGC. Mortality rates among patients with HDGC are high because the disease is challenging to diagnose early. E-cadherin functions as an adhesion protein that holds epithelial cells together; however, the mutated protein results in a mass of free-floating cancer cells that move and spread easily. HDGC has nonspecific symptoms, such as stomach acidity and burping, which further complicate diagnosis.
In addition, the malfunctioning e-cadherin leaves the membrane and is destroyed inside the cell. Without clear symptomatology, early diagnosis relies on searching for the lack of e-cadherin on the membrane. Test results for this effect are not reliable. The new method’s algorithm allows researchers to select more representative cells for testing.
How it works is that software designed to compute data from fluorescence images of the protein in a cell population generates a map of the protein distribution. The software then constructs 2D virtual images of a typical cell in that population, allowing researchers—and in the future clinicians—to measure the level of e-cadherin in the cell and predict the patient’s risk for HDGC.
This study focused on HDGC; however, e-cadherin mutations are known to be involved in other cancers as well, including breast, colorectal, thyroid, and ovarian cancers. The results from this study could also be applied to these cancers.
New method of identifying cancer risk that uses images of a protein in a population of cells.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|